Biogen, Samsung Bioepis look to carve up a blockbuster Roche franchise with deep discount biosimilar

Biogen and their biosimilar partners at Samsung Bioepis are rolling out their copycat version of Roche’s anti-VEGF blockbuster Lucentis today, 8 months after it was approved by the FDA. And they’re planning to dive straight into a wet AMD market dominated by Regeneron’s Eylea with a hefty 40% discount off...

Click to view original post